Foli A - Search Results

1

Mutations in the pol gene of human immunodeficiency virus type 1 in infected patients receiving didanosine and hydroxyurea combination therapy.

De Antoni A, Foli A, Lisziewicz J, Lori F. De Antoni A, et al. Among authors: foli a. J Infect Dis. 1997 Oct;176(4):899-903. doi: 10.1086/516511. J Infect Dis. 1997. PMID: 9333147 Clinical Trial.

2

Complementary antiviral efficacy of hydroxyurea and protease inhibitors in human immunodeficiency virus-infected dendritic cells and lymphocytes.

Piccinini G, Foli A, Comolli G, Lisziewicz J, Lori F. Piccinini G, et al. Among authors: foli a. J Virol. 2002 Mar;76(5):2274-8. doi: 10.1128/jvi.76.5.2274-2278.2002. J Virol. 2002. PMID: 11836405 Free PMC article.

3

Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Lisziewicz J, Foli A, Wainberg M, Lori F. Lisziewicz J, et al. Among authors: foli a. Drug Saf. 2003;26(9):605-24. doi: 10.2165/00002018-200326090-00002. Drug Saf. 2003. PMID: 12814330 Review.

4

Safety of hydroxyurea in the treatment of HIV infection.

Lori F, Kelly LM, Foli A, Lisziewicz J. Lori F, et al. Among authors: foli a. Expert Opin Drug Saf. 2004 Jul;3(4):279-88. doi: 10.1517/14740338.3.4.279. Expert Opin Drug Saf. 2004. PMID: 15268646 Review.

5

Optimal suppression of HIV replication by low-dose hydroxyurea through the combination of antiviral and cytostatic ('virostatic') mechanisms.

Lori F, Foli A, Groff A, Lova L, Whitman L, Bakare N, Pollard RB, Lisziewicz J. Lori F, et al. Among authors: foli a. AIDS. 2005 Jul 22;19(11):1173-81. doi: 10.1097/01.aids.0000176217.02743.d1. AIDS. 2005. PMID: 15990570 Clinical Trial.

6

Combination of a drug targeting the cell with a drug targeting the virus controls human immunodeficiency virus type 1 resistance.

Lori F, Malykh AG, Foli A, Maserati R, De Antoni A, Minoli L, Padrini D, Degli Antoni A, Barchi E, Jessen H, Wainberg MA, Gallo RC, Lisziewicz J. Lori F, et al. Among authors: foli a. AIDS Res Hum Retroviruses. 1997 Nov 1;13(16):1403-9. doi: 10.1089/aid.1997.13.1403. AIDS Res Hum Retroviruses. 1997. PMID: 9359660 Clinical Trial.

7

Hydroxyurea and didanosine long-term treatment prevents HIV breakthrough and normalizes immune parameters.

Lori F, Rosenberg E, Lieberman J, Foli A, Maserati R, Seminari E, Alberici F, Walker B, Lisziewicz J. Lori F, et al. Among authors: foli a. AIDS Res Hum Retroviruses. 1999 Oct 10;15(15):1333-8. doi: 10.1089/088922299310034. AIDS Res Hum Retroviruses. 1999. PMID: 10515148

8

Hydroxyurea and didanosine is a more potent combination than hydroxyurea and zidovudine.

Foli A, Lori F, Maserati R, Tinelli C, Minoli L, Lisziewicz J. Foli A, et al. Antivir Ther. 1997 Jan;2(1):31-8. Antivir Ther. 1997. PMID: 11322264 Clinical Trial.

9

Role of hydroxyurea during structured treatment interruptions.

Foli A, Seminari E, Ravot E, Lisziewicz J, Lori F. Foli A, et al. J Biol Regul Homeost Agents. 2002 Jan-Mar;16(1):64-8. J Biol Regul Homeost Agents. 2002. PMID: 12003177 Clinical Trial.

10

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency.

Lori F, Pollard RB, Whitman L, Bakare N, Blick G, Shalit P, Foli A, Peterson D, Tennenberg A, Schrader S, Rashbaum B, Farthing C, Herman D, Norris D, Greiger P, Frank I, Groff A, Lova L, Asmuth D, Lisziewicz J. Lori F, et al. Among authors: foli a. AIDS Res Hum Retroviruses. 2005 Apr;21(4):263-72. doi: 10.1089/aid.2005.21.263. AIDS Res Hum Retroviruses. 2005. PMID: 15943568 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

111 results

Search Page